Biopharmaceutical company Geron Corp. has granted a non-exclusive license to Procter & Gamble relating to Geron’s human telomerase reverse transcriptase (hTERT) technology for cell research applications. Financial terms of the agreement were not disclosed.
P&G plans to use the technology to create immortalized cell lines from certain types of skin cells to study the regulation of cell function and to develop biological tests for screening purposes.
Cell lines immortalized with hTERT technology can proliferate indefinitely while maintaining normal physical and biological characteristics, according to experts. Executives said this means P&G will be able to conduct repeated or long-term studies on the biology and functin of the cells.